Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Heated testimony as House panel weighs bill to limit manufacturer restrictions on 340B contract pharmacies
Summary
House Bill 2,145 would bar manufacturers and distributors from restricting acquisition or delivery of 340B drugs or conditioning access on claims data; testimony highlighted sharp divides between safety‑net providers and hospitals citing patient‑services reliance versus industry and employer groups warning of higher costs and lack of transparency.
Lawmakers in the House Health Care and Wellness Committee debated House Bill 2,145 on Jan. 20, a proposal to prevent manufacturers, distributors or third‑party logistics providers from denying, restricting, or conditioning access to drugs sold at 340B prices to covered entities or their contract pharmacies. The bill would also bar manufacturers from requiring claims, utilization, purchasing or other data as a condition of selling 340B drugs and would create civil remedies including possible daily penalties and enforcement by the attorney general under the Consumer Protection Act.
Staff counsel Emily Poole opened the discussion with a technical summary: 340B is a federal program (HRSA/HHS) that lets eligible safety‑net providers buy outpatient drugs at capped prices; federal law prohibits duplicate discounts and drug diversion and authorizes HRSA audits. Poole said the bill’s two core prohibitions are (1) barring manufacturers/distributors/3PLs from denying or restricting acquisition or delivery of 340B drugs to covered entities or contract pharmacies unless federal law prohibits it, and (2) banning manufacturers from…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
